Tuesday , 21 November 2017
Home » Health » Health Canada : Cancer drug maker’s licence reinstated
Health Canada : Cancer drug maker’s licence reinstated
Health Canada : Cancer drug maker's licence reinstated

Health Canada : Cancer drug maker’s licence reinstated

Health Canada has reinstated the licence of Biolyse Pharma. the manufacturer of the key cancer medication paclitaxel, allowing the Ontario company to resume operations with “amended terms and conditions.”

In April, Health Canada said that it had withdrawn the license for Biolyse facility because of “significant concerns with the manufacturing process,” but did not spell those out. The company said today that it has since demonstrated to Health Canada that its production is in compliance with the agency’s standards, pointing out that the reinspection was conducted by a “new team of Health Canada inspectors.”

Biolyse claimed that it supplies about 80% of the demand for the cancer drug from the Canadian market, selling it at $50 a dose, a price it says saves the national health system millions of dollars a year compared to what it would pay other manufacturers. Biolyse President Brigitte Kiecken last month said the company was scrambling to convince regulators that it was doing what was wanted and had warned that it would soon go out of business if competitors swooped in and took away its customers.

Agencies/Canadajournal




  • About News

    Web articles – via partners/network co-ordinators. This website and its contents are the exclusive property of ANGA Media Corporation . We appreciate your feedback and respond to every request. Please fill in the form or send us email to: [email protected]

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    *